Table I.
Baseline characteristics of the study group
| Phase I N=14 | Phase II N=19 | Phase I/II N=33 | |
|---|---|---|---|
| Gender | |||
| Female | 6 (43%) | 7 (37%) | 13 (39%) |
| Male | 8 (57%) | 12 (63%) | 20 (61%) |
| Age (years) | |||
| Median (range) | 59 (49, 85) | 61 (34, 87) | 59 (34, 87) |
| Primary diagnosis | |||
| AITL | - | 1 (5%) | 1 (3%) |
| ALCL | - | 1 (5%) | 1 (3%) |
| BCLU | 1 (7%) | - | 1 (3%) |
| CLL | - | 3 (16%) | 3 (9%) |
| DLBCL | 2 (14%) | 6 (32%) | 8 (24%) |
| ENKL | - | 1 (5%) | 1 (3%) |
| FL 1–2 | 5 (36%) | 2 (11%) | 7 (21%) |
| MCL | 1 (7%) | 1 (5%) | 2 (6%) |
| MZL/LPL | 2 (14%) | - | 2 (6%) |
| PTCL-NOS | 3 (21%) | 4 (21%) | 7 (21%) |
| Histology | |||
| B cell | 11 (79%) | 12 (63%) | 23 (70%) |
| T cell | 3 (21%) | 7 (37%) | 10 (30%) |
| Number of prior therapies | |||
| 0–3 | 7 (50%) | 12 (63%) | 19 (58%) |
| 4+ | 7 (50%) | 7 (37%) | 14 (42%) |
| Stage at enrolment | |||
| 3 | 4 (29%) | 2 (11%) | 6 (18%) |
| 4 | 10 (71%) | 16 (84%) | 26 (79%) |
| NA | 1 (5%) | 1 (3%) | |
| Prior rituximab | 11 (79%) | 11 (58%) | 22 (67%) |
| Prior autologous transplant | 1 (7%) | 7 (37%) | 8 (24%) |
| Number of cycles of dasatinib | |||
| 1 | 3 (21%) | 8 (42%) | 11 (33%) |
| 2 | 4 (29%) | 3 (16%) | 7 (21%) |
| 4 | 1 (7%) | 5 (26%) | 6 (18%) |
| 5 | - | 1 (5%) | 1 (3%) |
| 6 | 1 (7%) | - | 1 (3%) |
| 8 | 1 (7%) | 1 (5%) | 2 (6%) |
| 10 | 1 (7%) | - | 1 (3%) |
| 17 | 1 (7%) | - | 1 (3%) |
| 38 | - | 1 (5%) | 1 (3%) |
| 99 | 2 (14%) | - | 2 (6%) |
AITL: Angio-immunoblastic T-cell lymphoma; ALCL: Anaplastic large cell lymphoma; BCLU: Unclassifiable B-cell lymphoma; CLL: Chronic lymphocytic leukaemia; DLBCL: Diffuse large B-cell lymphoma; ENKL: Extra nodal Natural Killer/T-cell lymphoma; FL 1–2: Follicular lymphoma, Grade 1/2; MCL: Mantle cell lymphoma; MZL/LPL: Marginal zone lymphoma/Lymphoplasmacytic lymphoma; NA: not available; PTCL: NOS-Peripheral T-cell lymphoma, not otherwise specified.